Biogen Inc. (0R1B.L)
USD 118.01
(0.03%)
USD 118.01
(0.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.3 Billion USD | -7.51% |
| 2022 | 7.89 Billion USD | -11.01% |
| 2021 | 8.87 Billion USD | -23.78% |
| 2020 | 11.63 Billion USD | -6.3% |
| 2019 | 12.42 Billion USD | 6.75% |
| 2018 | 11.63 Billion USD | 9.33% |
| 2017 | 10.64 Billion USD | 6.76% |
| 2016 | 9.97 Billion USD | 4.69% |
| 2015 | 9.52 Billion USD | 11.62% |
| 2014 | 8.53 Billion USD | 40.46% |
| 2013 | 6.07 Billion USD | 22.2% |
| 2012 | 4.97 Billion USD | 8.49% |
| 2011 | 4.58 Billion USD | 6.16% |
| 2010 | 4.31 Billion USD | 8.03% |
| 2009 | 3.99 Billion USD | 8.11% |
| 2008 | 3.69 Billion USD | 30.29% |
| 2007 | 2.83 Billion USD | 77.52% |
| 2006 | 1.59 Billion USD | 19.24% |
| 2005 | 1.34 Billion USD | 28.66% |
| 2004 | 1.04 Billion USD | 164.04% |
| 2003 | 394.44 Million USD | -60.08% |
| 2002 | 988.2 Million USD | 8.97% |
| 2001 | 906.85 Million USD | 13.18% |
| 2000 | 801.25 Million USD | 17.24% |
| 1999 | 683.43 Million USD | 41.47% |
| 1998 | 483.07 Million USD | 25.85% |
| 1997 | 383.85 Million USD | 54.43% |
| 1996 | 248.56 Million USD | 76.05% |
| 1995 | 141.18 Million USD | -3.56% |
| 1994 | 146.39 Million USD | 11.84% |
| 1993 | 130.9 Million USD | 7.74% |
| 1992 | 121.5 Million USD | 571.27% |
| 1991 | 18.1 Million USD | 23.13% |
| 1990 | 14.7 Million USD | 345.45% |
| 1989 | 3.3 Million USD | 760.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.51 Billion USD | -14.56% |
| 2024 Q2 | 1.64 Billion USD | 9.12% |
| 2024 Q3 | 1.82 Billion USD | 10.85% |
| 2023 Q4 | 1.76 Billion USD | -5.49% |
| 2023 Q3 | 1.87 Billion USD | 0.4% |
| 2023 Q1 | 1.8 Billion USD | -8.76% |
| 2023 FY | 7.3 Billion USD | -7.51% |
| 2023 Q2 | 1.86 Billion USD | 3.51% |
| 2022 Q2 | 2.1 Billion USD | 18.4% |
| 2022 FY | 7.89 Billion USD | -11.01% |
| 2022 Q4 | 1.97 Billion USD | -3.23% |
| 2022 Q3 | 2.03 Billion USD | -3.14% |
| 2022 Q1 | 1.77 Billion USD | -14.26% |
| 2021 Q2 | 2.31 Billion USD | 4.49% |
| 2021 FY | 8.87 Billion USD | -23.78% |
| 2021 Q3 | 2.26 Billion USD | -2.08% |
| 2021 Q4 | 2.07 Billion USD | -8.53% |
| 2021 Q1 | 2.21 Billion USD | -6.19% |
| 2020 FY | 11.63 Billion USD | -6.3% |
| 2020 Q3 | 2.92 Billion USD | -10.5% |
| 2020 Q1 | 3.08 Billion USD | -4.47% |
| 2020 Q2 | 3.27 Billion USD | 6.19% |
| 2020 Q4 | 2.36 Billion USD | -19.3% |
| 2019 Q3 | 3.17 Billion USD | 0.95% |
| 2019 Q2 | 3.14 Billion USD | 8.75% |
| 2019 FY | 12.42 Billion USD | 6.75% |
| 2019 Q1 | 2.88 Billion USD | -4.94% |
| 2019 Q4 | 3.22 Billion USD | 1.71% |
| 2018 FY | 11.63 Billion USD | 9.33% |
| 2018 Q3 | 2.97 Billion USD | 1.45% |
| 2018 Q2 | 2.93 Billion USD | 9.33% |
| 2018 Q1 | 2.68 Billion USD | -4.03% |
| 2018 Q4 | 3.03 Billion USD | 2.0% |
| 2017 Q3 | 2.7 Billion USD | -0.16% |
| 2017 Q1 | 2.42 Billion USD | -2.7% |
| 2017 Q4 | 2.79 Billion USD | 3.32% |
| 2017 Q2 | 2.71 Billion USD | 11.79% |
| 2017 FY | 10.64 Billion USD | 6.76% |
| 2016 Q4 | 2.49 Billion USD | -1.79% |
| 2016 Q1 | 2.41 Billion USD | -3.74% |
| 2016 Q2 | 2.52 Billion USD | 4.56% |
| 2016 Q3 | 2.53 Billion USD | 0.59% |
| 2016 FY | 9.97 Billion USD | 4.69% |
| 2015 FY | 9.52 Billion USD | 11.62% |
| 2015 Q4 | 2.5 Billion USD | 1.61% |
| 2015 Q3 | 2.46 Billion USD | 7.04% |
| 2015 Q2 | 2.3 Billion USD | 2.81% |
| 2015 Q1 | 2.24 Billion USD | -4.3% |
| 2014 Q1 | 1.85 Billion USD | 8.39% |
| 2014 Q3 | 2.2 Billion USD | 3.72% |
| 2014 FY | 8.53 Billion USD | 40.46% |
| 2014 Q4 | 2.34 Billion USD | 6.09% |
| 2014 Q2 | 2.12 Billion USD | 15.08% |
| 2013 Q3 | 1.59 Billion USD | 6.72% |
| 2013 FY | 6.07 Billion USD | 22.2% |
| 2013 Q1 | 1.28 Billion USD | -0.22% |
| 2013 Q2 | 1.49 Billion USD | 16.5% |
| 2013 Q4 | 1.7 Billion USD | 7.17% |
| 2012 Q1 | 1.15 Billion USD | -2.38% |
| 2012 Q3 | 958.4 Million USD | -25.23% |
| 2012 Q4 | 1.28 Billion USD | 33.98% |
| 2012 Q2 | 1.28 Billion USD | 10.62% |
| 2012 FY | 4.97 Billion USD | 8.49% |
| 2011 FY | 4.58 Billion USD | 6.16% |
| 2011 Q4 | 1.18 Billion USD | 0.06% |
| 2011 Q3 | 1.18 Billion USD | 7.06% |
| 2011 Q2 | 1.1 Billion USD | 0.72% |
| 2011 Q1 | 1.1 Billion USD | -1.66% |
| 2010 Q1 | 1.01 Billion USD | -1.51% |
| 2010 FY | 4.31 Billion USD | 8.03% |
| 2010 Q4 | 1.11 Billion USD | 3.6% |
| 2010 Q3 | 1.07 Billion USD | -2.34% |
| 2010 Q2 | 1.1 Billion USD | 9.28% |
| 2009 Q4 | 1.02 Billion USD | 0.03% |
| 2009 Q3 | 1.02 Billion USD | 2.44% |
| 2009 FY | 3.99 Billion USD | 8.11% |
| 2009 Q1 | 938.28 Million USD | -3.04% |
| 2009 Q2 | 1 Billion USD | 6.85% |
| 2008 FY | 3.69 Billion USD | 30.29% |
| 2008 Q1 | 841.25 Million USD | 4.41% |
| 2008 Q2 | 901.04 Million USD | 7.11% |
| 2008 Q3 | 985.47 Million USD | 9.37% |
| 2008 Q4 | 967.75 Million USD | -1.8% |
| 2007 FY | 2.83 Billion USD | 77.52% |
| 2007 Q2 | 689.11 Million USD | 8.7% |
| 2007 Q3 | 707.61 Million USD | 2.69% |
| 2007 Q4 | 805.73 Million USD | 13.87% |
| 2007 Q1 | 633.96 Million USD | 485.09% |
| 2006 Q3 | 636.7 Million USD | 9.39% |
| 2006 Q4 | -164.62 Million USD | -125.86% |
| 2006 Q2 | 582.04 Million USD | 7.06% |
| 2006 Q1 | 543.68 Million USD | 387.08% |
| 2006 FY | 1.59 Billion USD | 19.24% |
| 2005 Q4 | -189.38 Million USD | -137.38% |
| 2005 FY | 1.34 Billion USD | 28.66% |
| 2005 Q2 | 534.54 Million USD | 9.49% |
| 2005 Q1 | 488.19 Million USD | 538.52% |
| 2005 Q3 | 506.65 Million USD | -5.22% |
| 2004 Q3 | 478.81 Million USD | 23.71% |
| 2004 Q4 | -111.32 Million USD | -123.25% |
| 2004 FY | 1.04 Billion USD | 164.04% |
| 2004 Q1 | 286.97 Million USD | 164.13% |
| 2004 Q2 | 387.03 Million USD | 34.87% |
| 2003 Q1 | 274.43 Million USD | 5.61% |
| 2003 Q3 | 287.51 Million USD | 2.69% |
| 2003 Q4 | -447.5 Million USD | -255.64% |
| 2003 Q2 | 280 Million USD | 2.03% |
| 2003 FY | 394.44 Million USD | -60.08% |
| 2002 Q3 | 246.27 Million USD | 5.67% |
| 2002 Q4 | 259.84 Million USD | 5.51% |
| 2002 Q2 | 233.05 Million USD | -6.41% |
| 2002 Q1 | 249.02 Million USD | 1.75% |
| 2002 FY | 988.2 Million USD | 8.97% |
| 2001 Q2 | 225.46 Million USD | 8.45% |
| 2001 Q3 | 228.73 Million USD | 1.45% |
| 2001 Q4 | 244.75 Million USD | 7.0% |
| 2001 FY | 906.85 Million USD | 13.18% |
| 2001 Q1 | 207.9 Million USD | -2.2% |
| 2000 Q1 | 188.22 Million USD | 9.41% |
| 2000 Q3 | 200.72 Million USD | 0.5% |
| 2000 Q2 | 199.71 Million USD | 6.11% |
| 2000 Q4 | 212.58 Million USD | 5.91% |
| 2000 FY | 801.25 Million USD | 17.24% |
| 1999 Q1 | 153.4 Million USD | 20.33% |
| 1999 Q3 | 187 Million USD | 9.48% |
| 1999 Q4 | 172.03 Million USD | -8.01% |
| 1999 FY | 683.43 Million USD | 41.47% |
| 1999 Q2 | 170.8 Million USD | 11.34% |
| 1998 Q2 | 117.6 Million USD | 11.68% |
| 1998 Q4 | 127.47 Million USD | -4.01% |
| 1998 FY | 483.07 Million USD | 25.85% |
| 1998 Q1 | 105.3 Million USD | -10.81% |
| 1998 Q3 | 132.8 Million USD | 12.93% |
| 1997 Q3 | 92.6 Million USD | 8.05% |
| 1997 FY | 383.85 Million USD | 54.43% |
| 1997 Q1 | 87.4 Million USD | 4.71% |
| 1997 Q2 | 85.7 Million USD | -1.95% |
| 1997 Q4 | 118.05 Million USD | 27.49% |
| 1996 FY | 248.56 Million USD | 76.05% |
| 1996 Q4 | 83.46 Million USD | -7.57% |
| 1996 Q3 | 90.3 Million USD | 119.71% |
| 1996 Q2 | 41.1 Million USD | 21.6% |
| 1996 Q1 | 33.8 Million USD | -36.34% |
| 1995 Q3 | 33.7 Million USD | 3.37% |
| 1995 Q4 | 53.09 Million USD | 57.54% |
| 1995 FY | 141.18 Million USD | -3.56% |
| 1995 Q2 | 32.6 Million USD | 2.52% |
| 1995 Q1 | 31.8 Million USD | -6.18% |
| 1994 FY | 146.39 Million USD | 11.84% |
| 1994 Q1 | 40.5 Million USD | 19.47% |
| 1994 Q2 | 32.5 Million USD | -19.75% |
| 1994 Q3 | 31.7 Million USD | -2.46% |
| 1994 Q4 | 33.89 Million USD | 6.93% |
| 1993 FY | 130.9 Million USD | 7.74% |
| 1993 Q2 | 32.8 Million USD | 4.13% |
| 1993 Q1 | 31.5 Million USD | -66.84% |
| 1993 Q4 | 33.9 Million USD | 3.99% |
| 1993 Q3 | 32.6 Million USD | -0.61% |
| 1992 FY | 121.5 Million USD | 571.27% |
| 1992 Q3 | 20 Million USD | 589.66% |
| 1992 Q4 | 95 Million USD | 375.0% |
| 1992 Q2 | 2.9 Million USD | -14.71% |
| 1992 Q1 | 3.4 Million USD | -5.56% |
| 1991 FY | 18.1 Million USD | 23.13% |
| 1991 Q2 | 5.3 Million USD | -5.36% |
| 1991 Q4 | 3.6 Million USD | 0.0% |
| 1991 Q3 | 3.6 Million USD | -32.08% |
| 1991 Q1 | 5.6 Million USD | 12.0% |
| 1990 Q1 | 3.8 Million USD | 1800.0% |
| 1990 Q4 | 5 Million USD | 56.25% |
| 1990 Q3 | 3.2 Million USD | 23.08% |
| 1990 Q2 | 2.6 Million USD | -31.58% |
| 1990 FY | 14.7 Million USD | 345.45% |
| 1989 Q2 | 6.9 Million USD | -14.81% |
| 1989 FY | 3.3 Million USD | 760.0% |
| 1989 Q1 | 8.1 Million USD | 44.64% |
| 1989 Q3 | 200 Thousand USD | -97.1% |
| 1989 Q4 | 200 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -42062.942% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -2417847.02% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -72616.59% |
| IQVIA Holdings Inc. | 5.23 Billion USD | -39.382% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -568.092% |
| Homology Medicines, Inc. | -7.22 Million USD | 101112.588% |
| Imunon, Inc. | -720 Thousand USD | 1014287.401% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 76434.936% |
| uniQure N.V. | 2.21 Million USD | -329570.429% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 8669.048% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -1917.015% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 2333071.246% |
| bluebird bio, Inc. | -4.03 Million USD | 181296.03% |
| Blueprint Medicines Corporation | 236.58 Million USD | -2986.515% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -49259.2% |
| Adicet Bio, Inc. | -6.09 Million USD | 119847.458% |
| Dynavax Technologies Corporation | 182.11 Million USD | -3909.62% |
| Geron Corporation | -123.5 Million USD | 6012.569% |
| Illumina, Inc. | 2.74 Billion USD | -166.115% |
| Myriad Genetics, Inc. | 476.4 Million USD | -1432.788% |
| Verastem, Inc. | -62 Thousand USD | 11777841.935% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 15.16% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 52.035% |
| Nektar Therapeutics | 53.47 Million USD | -13554.587% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 2500853.425% |
| Perrigo Company plc | 1.68 Billion USD | -334.551% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 37168.887% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -295.269% |
| Editas Medicine, Inc. | -99.52 Million USD | 7436.83% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -9893.841% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -236.651% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -1294.236% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 72.469% |
| Waters Corporation | 1.76 Billion USD | -314.617% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 23528.772% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -283.444% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 16210.756% |
| Evolus, Inc. | 140.52 Million USD | -5096.334% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 35.387% |
| FibroGen, Inc. | 128.9 Million USD | -5564.836% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -110.742% |
| OPKO Health, Inc. | 318.12 Million USD | -2195.373% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -381.077% |
| Exelixis, Inc. | 1.75 Billion USD | -315.45% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 1931.071% |
| Zoetis Inc. | 5.83 Billion USD | -25.166% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -2886.157% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 2410066.997% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -837.966% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -1434.417% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -1046.537% |
| Insmed Incorporated | 239.63 Million USD | -2947.218% |
| TG Therapeutics, Inc. | 219.1 Million USD | -3232.694% |
| Incyte Corporation | 3.44 Billion USD | -112.233% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -2023.35% |